

September 21, 2017

Vertex to Present at the Leerink Partners Roundtable Series on September 27

BOSTON--(BUSINESS WIRE)-- <u>Vertex Pharmaceuticals Incorporated</u> (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m. ET

Management's remarks will be available live through Vertex's website at <u>www.vrtx.com</u> in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For seven years in a row, *Science* magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit <u>www.vrtx.com</u>.

(VRTX-WEB)

View source version on businesswire.com: http://www.businesswire.com/news/home/20170921006078/en/

Vertex Pharmaceuticals Incorporated

Michael Partridge, 617-341-6108 or Eric Rojas, 617-961-7205 or Zach Barber, 617-341-6470

Source: Vertex Pharmaceuticals Incorporated

News Provided by Acquire Media